Compared with the control group, those assigned to SSRI and CBT-I coadministration had higher rates of both depression remission (62% to 33%) and Ibrutinib cost insomnia remission
(50% to 8%). Although the difference in rates of depression remission did not reach statistical significance, likely a function of the small sample size, these findings suggest that, insomnia and possibly depression can be successfully improved using nonpharmacological interventions. Several studies have reported improvements in depression severity Inhibitors,research,lifescience,medical following CBT-I. One small pilot study61 evaluated CBT-I for comorbid mild depression and insomnia, finding that all 8 participants who completed the CBT-I intervention no longer met criteria for insomnia, and all but, one participant reported normal posttreatment depression scores (Beck Depression Inventory scores <9).Two other reports that examined individuals with and without Inhibitors,research,lifescience,medical depression documented equivalent improvements in sleep following CBT-I62 or a self-help intervention that consisted of stimulus control, relaxation, and
cognitive components63; improvements in sleep were also associated with significant, reductions in selfreported depression severity. Further controlled trials are needed to replicate these findings, to examine Inhibitors,research,lifescience,medical whether the resolution of insomnia following CBT-I and/or pharmacotherapy leads to longer periods of depression remission, and whether targeted Inhibitors,research,lifescience,medical insomnia interventions favorably impact, sleep and depression in individuals whose insomnia emerges during treatment or remains
a residual symptom following an adequate antidepressant trial. These initial findings, however, suggest that both hypnotics and CBT-I may lead to improvements in depression and insomnia symptoms, and therefore such interventions may lead to depression remission that is more stable. Inhibitors,research,lifescience,medical Hypersomnia and fatigue Less research has examined the impact of hypersomnia on depression and its treatment. Although the symptom of hypersomnia is reported less often in patients with MDD, daytime sleepiness and fatigue are common symptoms of depression, and are also prevalent Dichloromethane dehalogenase in the prodromal and residual phases of MDD. Such symptoms can occur independently, or they may occur secondarily to sleep continuity difficulties or insomnia comorbidity, as well as short- or long-term side effects of antidepressant medications. Fatigue is the second most, common residual symptom in depression.45 Like insomnia, treating daytime sleepiness and fatigue within the context of depression may favorably impact remission. Modafinil is a novel psychostimulant approved to treat excessive daytime sleepiness in narcolepsy sleep apnea, and shift work sleep disorder.